DTIL forecasts a Q2 2026 EPS loss of $0.69 and revenue of $0.74M, reflecting year-over-year improvements.
Precision BioSciences (DTIL) will report Q2 2026 earnings on August 6 before the market opens. Analysts expect a loss of $0.69 per share, an improvement of 67.6% year-over-year, alongside revenue of $0.74M.
In the past year, DTIL has frequently surpassed earnings estimates, though revenue performance has varied. The company’s focus on gene editing therapies continues to drive investor interest amid evolving biotech sector dynamics.
Market reaction will hinge on whether DTIL meets or exceeds the consensus estimates, particularly given its history of earnings beats.